TY - JOUR
T1 - Non-tuberculous mycobacterial infections—A neglected and emerging problem
AU - Ahmed, Imran
AU - Tiberi, Simon
AU - Farooqi, Joveria
AU - Jabeen, Kauser
AU - Yeboah-Manu, Dorothy
AU - Migliori, Giovanni Battista
AU - Hasan, Rumina
N1 - Funding Information:
This project is part of the activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020-GBM/RC/LDA. This article is part of a supplement entitled Commemorating World Tuberculosis Day March 24th, 2020: “IT'S TIME TO FIND, TREAT ALL and END TUBERCULOSIS!” published with support from an unrestricted educational grant from QIAGEN Sciences Inc.
Publisher Copyright:
© 2020
PY - 2020/3
Y1 - 2020/3
N2 - Non-tuberculous mycobacteria (NTM) are ubiquitous dwellers of environmental niches and are an established cause of natural and nosocomial infections. The incidence of NTM infections is rising owing to a growing population of immunocompromised and vulnerable individuals, complex medical and surgical procedures, as well as increased awareness and diagnostic capabilities. The prevalence of different NTM varies between continents, regions, and countries. The true global burden of pulmonary and extrapulmonary disease is unknown and estimates are subject to under and/or over-estimation. Diagnosis requires confirmation by isolation of NTM along with clinical and radiological criteria, which may be suboptimal at all levels. Susceptibility testing is complex and clinical breakpoints are not available for many of the drugs. Frequently, NTM infections are not considered until late in the course of disease. Improved and rapid detection of tuberculosis cases in high-burden countries has, however, also brought NTM infections into the limelight, and has identified a need for research efforts towards rapid diagnostic tests and the identification of biomarkers to monitor the treatment response in patients with NTM infections.
AB - Non-tuberculous mycobacteria (NTM) are ubiquitous dwellers of environmental niches and are an established cause of natural and nosocomial infections. The incidence of NTM infections is rising owing to a growing population of immunocompromised and vulnerable individuals, complex medical and surgical procedures, as well as increased awareness and diagnostic capabilities. The prevalence of different NTM varies between continents, regions, and countries. The true global burden of pulmonary and extrapulmonary disease is unknown and estimates are subject to under and/or over-estimation. Diagnosis requires confirmation by isolation of NTM along with clinical and radiological criteria, which may be suboptimal at all levels. Susceptibility testing is complex and clinical breakpoints are not available for many of the drugs. Frequently, NTM infections are not considered until late in the course of disease. Improved and rapid detection of tuberculosis cases in high-burden countries has, however, also brought NTM infections into the limelight, and has identified a need for research efforts towards rapid diagnostic tests and the identification of biomarkers to monitor the treatment response in patients with NTM infections.
KW - Diagnosis
KW - Epidemiology
KW - Non-tuberculous mycobacteria
KW - Tuberculosis endemic regions
UR - http://www.scopus.com/inward/record.url?scp=85081257044&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2020.02.022
DO - 10.1016/j.ijid.2020.02.022
M3 - Article
C2 - 32114200
AN - SCOPUS:85081257044
SN - 1201-9712
VL - 92
SP - S46-S50
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -